Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Allogeneic stem cell transplantation in chronic myeloid leukemia patients: Single center experience
Nur Soyer, Ayse Uysal, Murat Tombuloglu, Fahri Sahin, Guray Saydam, Filiz Vural, Department of Hematology, Ege University Medical Faculty, 35100 Izmir, Turkey
Author contributions: Soyer N, Uysal A, Tombuloglu M, Sahin F, Saydam G and Vural F have been involved equally and have read and approved the final manuscript; Soyer N, Uysal A, Tombuloglu M, Sahin F, Saydam G and Vural F meet the criteria for authorship established by the International Committee of Medical Journal Editors and verify the validity of the results reported.
Conflict-of-interest statement: No.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Nur Soyer, MD, Department of Hematology, Ege University Medical Faculty, Ankara Blvd, Bornova, 35100 Izmir, Turkey. drakadnur@yahoo.com
Telephone: +90-232-3904541 Fax: +90-232-3738797
Received: August 23, 2016
Peer-review started: August 24, 2016
First decision: October 20, 2016
Revised: October 21, 2016
Accepted: January 2, 2017
Article in press: January 3, 2017
Published online: February 6, 2017
Processing time: 149 Days and 4.8 Hours
Peer-review started: August 24, 2016
First decision: October 20, 2016
Revised: October 21, 2016
Accepted: January 2, 2017
Article in press: January 3, 2017
Published online: February 6, 2017
Processing time: 149 Days and 4.8 Hours
Core Tip
Core tip: Tyrosine kinase inhibitors (TKIs) have changed the fatal outcomes of chronic myeloid leukemia (CML). Many studies showed that TKIs provided rapid response, few serious adverse event and impressive survival outcomes. Although, allogeneic stem cell transplantation (ASCT) is only curative treatment option for CML, since 1999, the numbers of ASCT have dropped. Currently, ASCT is offering for patients who are resistant or intolerant to at least one second generation TKI or for patients with blastic phase. Here, we present our center’s outcomes of ASCT for patients with CML and then, we discuss the place of ASCT in CML treatment in the TKIs era.